Physician profile
Kyle Watson
NPI 1316328214
$2,835.04
in general payments reported to CMS, 2019-2025
22 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $272 · 2022: $583 · 2023: $274 · 2024: $626 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $826.14 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $593.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $352.08 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $277.20 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $164.85 | 2023-2025 | |
| Ardelyx, INC. | $101.87 | 2025 | Ibsrela |
| Corcept Therapeutics | $78.95 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $63.02 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Amgen INC. | $43.81 | 2023-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $43.57 | 2021-2022 | |
| Abbott Laboratories | $40.51 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $39.91 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $34.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.32 | 2022-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $20.49 | 2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $19.10 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.28 | 2024 | Xifaxan |
| Dexcom, INC. | $17.58 | 2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $17.45 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.13 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.05 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $15.37 | 2023 | Verquvo, Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.